Genagon Therapeutics Overview
- Year Founded
-
2015
- Status
-
Out of Business
- Employees
-
10
- Latest Deal Type
-
Out of Business
Genagon Therapeutics General Information
Description
Developer of bio-pharmaceutical products designed to increase response rates in immuno-oncology. The company develops a platform helping to identify pathways in immune cells, discover a mechanism that cancers use to inhibit the innate immune system and offer treatment for oncology and inflammatory diseases, enabling the healthcare sector with discoveries of unstudied proteins.
Contact Information
Website
www.genagon.comCorporate Office
- Nanna Svartz Väg 2
- 171 65 Solna
- Sweden
Corporate Office
- Nanna Svartz Väg 2
- 171 65 Solna
- Sweden
Genagon Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Out of Business | 23-Dec-2023 | Completed | Out of Business | |||
| 8. Later Stage VC | 25-Mar-2021 | Completed | Clinical Trials - Phase 2 | |||
| 7. Accelerator/Incubator | 01-Jan-2020 | Completed | Clinical Trials - Phase 2 | |||
| 6. Early Stage VC | 31-Dec-2019 | Completed | Clinical Trials - Phase 2 | |||
| 5. Early Stage VC | 31-Dec-2018 | Completed | Clinical Trials - Phase 2 | |||
| 4. Early Stage VC | 31-Dec-2017 | Completed | Clinical Trials - Phase 2 | |||
| 3. Grant | 14-Mar-2017 | Completed | Clinical Trials - Phase 2 | |||
| 2. Seed Round | 26-Jan-2016 | $1.06M | $1.06M | Completed | Clinical Trials - Phase 2 | |
| 1. Accelerator/Incubator | 01-Jan-2015 | Completed | Startup |
Genagon Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Preference | ||||||||
| Preference | ||||||||
| Preference | 15,000 | $58.31 | $58.31 | 1x | $58.31 | 12.06% | ||
| Seed | 22,525 | $42.4 | $42.4 | 1x | $42.4 | 18.12% |
Genagon Therapeutics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Genagon Therapeutics Patents
Genagon Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202312099-D0 | Polypeptides | Inactive | 08-Aug-2023 | ||
| GB-202312096-D0 | Therapeutic agents | Inactive | 08-Aug-2023 | ||
| GB-202211575-D0 | Polypeptides | Inactive | 09-Aug-2022 | ||
| GB-202211576-D0 | Therapeutic agents | Inactive | 09-Aug-2022 | ||
| GB-202111640-D0 | Polypeptides | Inactive | 13-Aug-2021 |
Genagon Therapeutics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Genagon Therapeutics FAQs
-
When was Genagon Therapeutics founded?
Genagon Therapeutics was founded in 2015.
-
Where is Genagon Therapeutics headquartered?
Genagon Therapeutics is headquartered in Solna, Sweden.
-
What is the size of Genagon Therapeutics?
Genagon Therapeutics has 10 total employees.
-
What industry is Genagon Therapeutics in?
Genagon Therapeutics’s primary industry is Drug Discovery.
-
Is Genagon Therapeutics a private or public company?
Genagon Therapeutics is a Private company.
-
What is Genagon Therapeutics’s current revenue?
The current revenue for Genagon Therapeutics is .
-
How much funding has Genagon Therapeutics raised over time?
Genagon Therapeutics has raised $10.1M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
